These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38555280)

  • 1. Expression and functional implications of YME1L in nasopharyngeal carcinoma.
    Cheng F; Huang H; Yin S; Liu JS; Sun P
    Cell Death Dis; 2024 Jun; 15(6):423. PubMed ID: 38890304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Chaperonin HSP60: Current Understanding and Future Prospects.
    Singh MK; Shin Y; Han S; Ha J; Tiwari PK; Kim SS; Kang I
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K/AKT/mTOR signaling pathway inhibitors enhance radiosensitivity in cancer cell lines.
    Mardanshahi A; Gharibkandi NA; Vaseghi S; Abedi SM; Molavipordanjani S
    Mol Biol Rep; 2021 Aug; 48(8):1-14. PubMed ID: 34357550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PQR309, a dual PI3K/mTOR inhibitor, synergizes with gemcitabine by impairing the GSK-3β and STAT3/HSP60 signaling pathways to treat nasopharyngeal carcinoma.
    Cao J; Zeng K; Chen Q; Yang T; Lu F; Lin C; Zhan J; Ma W; Zhou T; Huang Y; Luo F; Zhao H
    Cell Death Dis; 2024 Mar; 15(3):237. PubMed ID: 38555280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
    Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma.
    Liu T; Sun Q; Li Q; Yang H; Zhang Y; Wang R; Lin X; Xiao D; Yuan Y; Chen L; Wang W
    Mol Cancer Ther; 2015 Feb; 14(2):429-39. PubMed ID: 25504751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment with angiotensin-(1-7) inhibits tumor growth via autophagy by downregulating PI3K/Akt/mTOR signaling in human nasopharyngeal carcinoma xenografts.
    Lin YT; Wang HC; Chuang HC; Hsu YC; Yang MY; Chien CY
    J Mol Med (Berl); 2018 Dec; 96(12):1407-1418. PubMed ID: 30374682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models.
    von Achenbach C; Weller M; Kaulich K; Gramatzki D; Zacher A; Fabbro D; Reifenberger G; Szabó E
    J Neurochem; 2020 May; 153(4):510-524. PubMed ID: 31618458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ADORA1 promotes nasopharyngeal carcinoma cell progression through regulation of PI3K/AKT/GSK-3β/β-catenin signaling.
    Pan S; Liang S; Wang X
    Life Sci; 2021 Aug; 278():119581. PubMed ID: 33961854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-222-3p-containing macrophage-derived extracellular vesicles confer gemcitabine resistance via TSC1-mediated mTOR/AKT/PI3K pathway in pancreatic cancer.
    Guo Y; Wu H; Xiong J; Gou S; Cui J; Peng T
    Cell Biol Toxicol; 2023 Aug; 39(4):1203-1214. PubMed ID: 35974258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mitochondrial unfolded protein response inhibitor suppresses prostate cancer growth in mice via HSP60.
    Kumar R; Chaudhary AK; Woytash J; Inigo JR; Gokhale AA; Bshara W; Attwood K; Wang J; Spernyak JA; Rath E; Yadav N; Haller D; Goodrich DW; Tang DG; Chandra D
    J Clin Invest; 2022 Jul; 132(13):. PubMed ID: 35653190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes.
    Zhou Z; Li P; Zhang X; Xu J; Xu J; Yu S; Wang D; Dong W; Cao X; Yan H; Sun M; Ding X; Xing J; Zhang P; Zhai L; Fan T; Tian S; Yang X; Hu M
    Mol Med; 2022 May; 28(1):55. PubMed ID: 35562651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.
    Collins GP; Eyre TA; Schmitz-Rohmer D; Townsend W; Popat R; Giulino-Roth L; Fields PA; Krasniqi F; Soussain C; Stathis A; Andjelkovic N; Cunningham D; Mandic D; Radulovic S; Tijanic I; Horowitz NA; Kurtovic S; Schorb E; Schmidt C; Dimitrijević S; Dreyling M
    Hemasphere; 2021 Nov; 5(11):e656. PubMed ID: 34901759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling.
    Zhang B; Luk C; Valadares J; Aronis C; Foukas LC
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884613
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.